Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2006; 131(21): 1223-1227
DOI: 10.1055/s-2006-941757
DOI: 10.1055/s-2006-941757
Aktuelle Diagnostik & Therapie | Review article
Angiologie
© Georg Thieme Verlag KG Stuttgart · New York
Raynaud-Phänomen - Aktuelle Diagnostik und Therapie
Current diagnostic and treatment of Raynaud’s phenomenonFurther Information
Publication History
eingereicht: 6.3.2006
akzeptiert: 25.4.2006
Publication Date:
23 May 2006 (online)
Schlüsselwörter
Raynaud-Phänomen - akrale Vasospastik - Sklerodermie - Vibrationssyndrom
Key words
Raynaud’s phenomenon - digital vasospasm - scleroderma - vibration white finger syndrome
Literatur
- 1 Anderson M E, Moore T L. et al . Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology. 2002; 41 324-328
- 2 Appiah R, Hiller H, Caspary L, Creutzig A, Alexander K. Treatment of primary RaynaudŽs syndrome with traditional Chinese acupuncture. J Intern Med. 1997; 241 119-124
- 3 Boin F, Wigley F M. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol. 2005; 17 752-760
- 4 Bukhari M, Hollis S, Moore T, Jayson M IV, Herrick A L. Quantitation of microcircular abnormalities in patients with primary Raynaud’s phenomenon and systemic sclerosis by video capillaroscopy. Rheumatology. 2000; 39 506-512
- 5 Cazelets C, Cador B, Rolland Y. et al . Exploration de la microcirculation pulpaire par écho-Doppler digitale chez des patients présentant une maladie de Raynaud ou une sclérocermie. J Mal Vasc. 2004; 29 12-20
- 6 Coleiro B, Marshall S E, Denton C P. et al . Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetin. Rheumatology. 2001; 40 1038-1043
- 7 Creutzig A, Freund M, Caspary L, Alexander K. Microangiopathy in patients with chronic myelogenous leukemia treated with interferon. Microvasc Res. 1996; 52 288-292
- 8 Czupryniak A, Kaluzynska A, Nowicki M. et al . Raynaud’s Phenomenon and Endothelial Dysfunction in End-Stage Renal Disease Patients Treated with Hemodialysis. Kidney Blood Press Res. 2005; 28 27-31
- 9 Gemne G, Pyykkö I, Taylor W. et al . The Stockholm Workshop scale for the classification of cold-induced Raynaud’s phenomenon in the hand-arm vibration syndrome (revision of the Taylor-Pelmaer scale). Scand J Work Environ Health. 1987; 13 275-278
- 10 Marasini B, Massarotti M, Bottasso B. et al . Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004; 33 253-256
- 11 Rosenkranz S, Caglayan E, Diet F. et al . Langzeiteffekte von Sildenafil bei Sklerodermie-assoziierter pulmonaler Hypertonie und Raynaud-Syndrom. Dtsch Med Wochenschr. 2004; 129 1736-1740
- 12 Thompson A E, Pope J E. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology. 2005; 44 145-150
- 13 von Bierbrauer A, Schilk I, Lucke C, Schmidt J A. Infrared thermography in the diagnosis of Raynaud’s phenomenon in vibration-induced white finger. Vasa. 1998; 27 94-99
- 14 Wörnle M, Tatò F, Hoffmann U. Hypothenar-Hammer-Syndrom als Ursache einer schweren digitalen Ischämie. Dtsch Med Wochenschr. 2004; 129 2352-2355
- 15 Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y. New therapeutic strategies for systemic sclerosis - a critical analysis of the literature. Clin Dev Immunol. 2005; 12 165-173
Priv.-Doz. Dr. med. Ludwig Caspary
Angiologische Gemeinschaftspraxis
Luisenstraße 10/11
30159 Hannover
Phone: 0511/3681830
Fax: 0511/3681930
Email: LCaspary@t-online.de